Cencora (COR) Q2 FY26 earnings call: guidance and Q&A

How do WAC/IRA reductions, lost business and the lower-margin mail shift affect operating profit, and do they change long-term revenue or operating-profit growth rates?

Cleary walked through Q2 revenue drivers (specialty volume, GLP-1 +$1.9B) and headwinds ($2B WAC/IRA = 3% US revenue drag, oncology/grocery customer losses, faster mail brand conversions), then operating-income drivers, and reaffirmed the long-term algorithm of 7-10% organic OI growth + 3-4% capital deployment = 10-14% EPS growth. Mauch added that revenue-pressuring items are low-margin and Cencora recoups WAC-decrease value, which is why they guide on operating income.

“we continue to have confidence in our long-term guidance, which is, of course, 7% to 10% organic operating income growth, another 3% to 4% from capital deployment and 10% to 14% EPS growth.”

asked by Lisa Gill · answered by James Cleary

Risk-weight where confidence is highest versus most variable in the US operating-income acceleration into the back half.

Cleary reiterated the guidance updates and cited supports for back-half acceleration: lapping the July 2025 oncology-customer loss, OneOncology accretion ramping, easier Q4 US expense comps, continued global specialty logistics growth with easier comps, and the MWI held-for-sale accounting benefit.

“there's the lapping of the loss of the oncology customer due to its acquisition in July 2025. We also see... OneOncology accretion ramping over the fiscal year, and we also see an easier expense comparison for our U.S. Healthcare Solutions segment in the fourth quarter.”

asked by Michael Cherny · answered by James Cleary

What long-term impact will generic/biosimilar conversions have on distribution operating profit, especially in specialty?

Mauch separated Part D mail (a product moving brand-to-biosimilar likely leaves the wholesaler — a revenue hit but not a meaningful profit hit, and already in the model) from Part B (GPO/MSO presence, where brand-to-biosimilar conversion is incrementally beneficial to the practice and to Cencora). No unknown pressure from Part D biosimilar growth; benefit as Part B biosimilars grow.

“as a product converts from the brand to the biosimilar in that space, it actually is incrementally beneficial to to the practice and to Cencora.”

asked by Glen Santangelo · answered by Robert Mauch

How is OneOncology tracking on a run-rate basis versus expectations, and how are synergies/integration progressing?

Mauch expressed strong satisfaction with full OneOncology ownership and RCA collaboration, with joint teams transferring best practices; volumes rebound after weather. Cleary added OneOncology and RCA have both been significant contributors to specialty growth for several years.

“we're really happy that OneOcology and RCA are now able to work more closely together along with the expertise that we have within Cencora to make sure that we're driving long-term value.”

asked by Elizabeth Anderson · answered by Robert Mauch

What is the basis for value in manufacturer negotiations amid AMP/price and GLP-1 reductions (1/1/2027), and how confident are you in maintaining absolute margin on lower prices?

Mauch expressed high confidence in maintaining dollar profit, citing the scope, scale and quality of services (ordering technology, automated distribution, secure handling) that would be impossible to replicate; cited an HDA study valuing distribution services at ~$80B/year to the health system. Stressed it is a commercial relationship where value must be demonstrated continually.

“those services contribute about $80 billion a year to the health care system.”

asked by Eric Percher · answered by Robert Mauch

Do you still earn margin on mail revenue, why was the conversion speed faster than expected, and were there other unlapped customer losses?

Mauch said the faster brand-to-biosimilar conversion speed was not planned for and is unusual versus historically slower PBM/mail transitions; wholesalers typically do not retain in-sourced generics/biosimilars, so the model played out as expected. Cleary confirmed brand sales to this customer are low margin (revenue-impactful, not meaningful to operating income) and that beyond the disclosed oncology and grocery customers, nothing else is sizeable enough to call out; smaller moves are contemplated in guidance.

“What we've called out here was that the pace of conversion was faster than we had anticipated.”

asked by Charles Rhyee · answered by Robert Mauch

Is the ex-OneOncology/ex-oncology-loss 7% US EBIT growth actually ~9% before COVID and weather, and how much are GLP-1s missing plus injectable-to-oral profitability impact?

Cleary confirmed the ~$10M weather and ~$10M COVID-19 vaccine operating-income headwinds — together $20M — would have lifted the quarter's operating-income growth higher within the long-term range if added back. (GLP-1 magnitude addressed elsewhere: ~$2B annual from a 5% growth delta.)

“if you add back for both of those things, our operating income would have been $20 million higher during the quarter.”

asked by Allen Lutz · answered by James Cleary

How sustainable is World Courier growth through the rest of the year beyond easier comps?

Mauch attributed the rebound to a biotech market that is stable-to-improving plus self-help (commercial rightsizing, pricing, efficiency), with multiple quarters of operating-income and volume growth. Cleary expressed good confidence in international guidance across distribution, 3PL and World Courier.

“we're really happy to see multiple quarters now of operating income growth and also volume growth within the business”

asked by Daniel Grosslight · answered by Robert Mauch

Why did core (ex one-timers) EBIT growth slow to ~7%, and why was the pressure in opex leverage rather than gross margin?

Cleary said core operating-income growth was in line with the long-term guide despite weather and COVID softness (adding those back moves it up within the range). He explained high reported opex growth reflects MSOs — whose income-statement shape differs from core distribution — and that ex-MSO opex grew ~5% constant currency; MSOs lift both gross and operating margin, so operating leverage should be viewed ex-MSO.

“if you back out the MSO business, our operating expense growth rate in the quarter on a constant currency basis was about 5%.”

asked by Kevin Caliendo · answered by James Cleary

Do long-term MSO acquisition opportunities remain, and how do they balance against timing/magnitude of buybacks?

Cleary reaffirmed balanced capital deployment (CapEx, strategic M&A, opportunistic buybacks, growing dividend), noting the buyback pause was for acquisitions, $500M term-loan paydown YTD ($1.3B planned), ~$3B FCF target, and $1B of buybacks by calendar year-end. He cited the iSouth acquisition and good MSO bolt-on opportunities.

“we're planning on doing $1 billion between now and the end of the calendar year.”

asked by Erin Wilson Wright · answered by James Cleary

What portion of US segment AOI comes from physician-administered (Part B) versus the other businesses, pro forma for iSouth?

Cleary declined to provide the Part B vs Part D earnings split, saying it is not how they present financials but they continually evaluate the best disclosure. Bennett Murphy clarified FY26 guidance includes no iSouth contribution and noted RCA has lapped its one-year annualization while OneOncology will continue to ramp.

“that's not the way that we present the financials now, but it's something that we're always evaluating what is the best way to talk about our business”

asked by George Hill · answered by James Cleary